Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions

Acta Ophthalmologica

Volumn 94, Issue 3, 2016, Pages e225-e230

  Tomomatsu, Yoko ^a   Tomomatsu, Takeshi ^a   Takamura, Yoshihiro ^a   Gozawa, Makoto ^a   Arimura, Shogo ^a   Takihara, Yuji ^a   Inatani, Masaru ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

best corrected visual acuity; bevacizumab; branch retinal vein occlusion; central retinal thickness; fluorescein angiography; macular oedema; non perfused areas; photocoagulation; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; LASER COAGULATION; MACULAR EDEMA; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PATIENT MONITORING; PHOTOCOAGULATOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RETINA ISCHEMIA; RETREATMENT; TARGETED RETINAL PHOTOCOAGULATION; TREATMENT RESPONSE; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; COMPLICATION; INTRAVITREAL DRUG ADMINISTRATION; ISCHEMIA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; PROSPECTIVE STUDY; RETINAL VEIN OCCLUSION;

AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; COMBINED MODALITY THERAPY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; ISCHEMIA; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84929921454     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12721     Document Type: Article

References (31)

1. Arnarsson Á, &, Stefánsson E, (2000): Laser treatment and the mechanism of edema reduction in branch retinal vein occlusion. Invest Ophthalmol Vis Sci 41: 877-879.
2. Avitabile T, Longo A, &, Reibaldi A, (2005): Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 140: 695-702.
3. Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley MR, &, Khan S, (2006): Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 26: 871-876.
4. Campochiaro PA, Hafiz G, Shah SM, et al., (2008): Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 16: 791-799.
5. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, &, Rubio RG, (2010): Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117: 1102-1112. e1101.
6. Campochiaro PA, Sophie R, Pearlman J, et al., (2014): Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121: 209-219.
7. Chen CH, Chen YH, Wu PC, Chen YJ, Lee JJ, Liu YC, &, Kuo HK, (2010): Treatment of branch retinal vein occlusion induced macular edema in treatment-naive cases with a single intravitreal triamcinolone or bevacizumab injection. Chang Gung Med J 33: 424-435.
8. Chung EJ, Hong YT, Lee SC, Kwon OW, &, Koh HJ, (2008): Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 246: 1241-1247.
9. Ehlers JP, &, Fekrat S, (2011): Retinal vein occlusion: beyond the acute event. Surv Ophthalmol 56: 281-299.
10. Figueroa MS, Contreras I, Noval S, &, Arruabarrena C, (2010): Results of bevacizumab as the primary treatment for retinal vein occlusions. Br J Ophthalmol 94: 1052-1056.
11. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, &, Samama MM, (1996): Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology 103: 551-560.
12. Higashiyama T, Sawada O, Kakinoki M, Sawada T, Kawamura H, &, Ohji M, (2013): Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmol 91: 318-324.
13. Jonas J, Paques M, Mones J, &, Glacet-Bernard A, (2010): Retinal vein occlusions. Dev Ophthalmol 47: 111-135.
14. Korobelnik JF, Holz FG, Roider J, et al., (2014): Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 121: 202-208.
15. Koss MJ, Pfister M, Rothweiler F, Michaelis M, Cinatl J, Schubert R, &, Koch FH, (2012): Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol 90: 98-103.
16. Kreutzer TC, Alge CS, Wolf AH, et al., (2008): Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 92: 351-355.
17. Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, &, Schmidt-Erfurth U, (2008): Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 92: 518-522.
18. Lopez-Garcia JS, Garcia-Lozano I, Rivas L, Ramirez N, Raposo R, &, Mendez MT, (2014): Autologous serum eye drops diluted with sodium hyaluronate: clinical and experimental comparative study. Acta Ophthalmol 92: 22-29.
19. Muqit MM, Marcellino GR, Henson DB, Young LB, Patton N, Charles SJ, Turner GS, &, Stanga PE, (2013): Optos-guided pattern scan laser (Pascal)-targeted retinal photocoagulation in proliferative diabetic retinopathy. Acta Ophthalmol 91: 251-258.
20. Noma H, Funatsu H, Yamasaki M, et al., (2005): Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 140: 256-261.
21. Noma H, Funatsu H, Mimura T, &, Shimada K, (2011): Influence of ischaemia on visual function in patients with branch retinal vein occlusion and macular edema. Clin Ophthalmol 5: 679-685.
22. Park SP, &, Ahn JK, (2008): Changes of aqueous vascular endothelial growth factor and interleukin-6 after intravitreal triamcinolone for branch retinal vein occlusion. Clin Experiment Ophthalmol 36: 831-835.
23. Pielen A, Mirshahi A, Feltgen N, et al., (2015): Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmol 93: 29-37.
24. Prasad PS, Oliver SC, Coffee RE, Hubschman JP, &, Schwartz SD, (2010): Ultra wide-field angiographic characteristics of branch retinal and hemicentral retinal vein occlusion. Ophthalmology 117: 780-784.
25. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, &, Avery RL, (2007): Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27: 419-425.
26. Simons BD, &, Brucker AJ, (1997): Branch retinal vein occlusion. Axial length and other risk factors. Retina 17: 191-195.
27. Sperduto RD, Hiller R, Chew E, et al., (1998): Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion: the eye disease case-control study. Ophthalmology 105: 765-771.
28. Takamura Y, Tomomatsu T, Matsumura T, Arimura S, Gozawa M, Takihara Y, &, Inatani M, (2014): The effect of photocoagulation in ischemic areas to prevent recurrence of diabetic macular edema after intravitreal bevacizumab injection. Invest Ophthalmol Vis Sci 55: 4741-4746.
29. Wong TY, &, Scott IU, (2010): Clinical practice. Retinal-vein occlusion. N Engl J Med 363: 2135-2144.
30. Wu L, Arevalo JF, Berrocal MH, Maia M, Roca JA, Morales-Canton V, Alezzandrini AA, &, Diaz-Llopis MJ, (2009): Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months. Retina 29: 1396-1403.
31. Yang LP, &, McKeage K, (2014): Intravitreal aflibercept (eylea): a review of its use in patients with macular oedema secondary to central retinal vein occlusion. Drugs Aging 31: 395-404.